Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PET, FEA

AniCura presents the Quality and Sustainability Report for 2020


STOCKHOLM, March 31, 2021 /PRNewswire/ -- Since 2015, AniCura has issued an annual quality report covering the developments within quality and patient safety as well as a reduction of antibiotic use among AniCura's clinics. The report for 2020 describes the developments during COVID-19 and best practices in veterinary care, people and the benefits of strong company values.

AniCura continues to stand strong and grow rapidly as a leading provider of modern high-quality veterinary care for pets. As our previous five reports, our aim is to share the learnings from our work and provide insights into AniCura. New for this year, is how we as a company have undertaken the many challenges caused by COVID-19 and how AniCura's strong company values have helped us to become even better, says Azita Shariati, CEO AniCura.

In 2020, AniCura's continued work in encouraging professional development and specialization has progressed with increased focus. In addition, the report describes AniCura's work within digitalization including digital veterinary services to pet owners in all Scandinavian countries.

Wiser antibiotic use is a never ending strive for AniCura. In a five-year period, the use of antibiotics in AniCura's veterinary hospitals and clinics in Europe has declined with almost 50 percent. In 2020, AniCura released its antibiotic guidelines for the eight most common indications for systemic antibiotic use.

Infection prevention

To ensure patient and employee safety, compliance with dress code and proper laundry procedures are important. For the first time, AniCura conducted a survey among 130 clinics in nine countries and completed 1,239 real-time dress code observations. The result show that 74% of the clinics have appointed an infection control practitioner for improved control and that 83% of the clinics have documented infection control routines in place.

Improved operational excellence in clinics

In 2018, the digital AniCura Patient Safety Improvement System (APSIS) was launched as a tool for enabling clinics to systematically document, analyze and learn from medical incidents. In 2020, 92% of the incidents were determined preventable. Enabling good incident handling takes time, requires correct communication skills, but is worthwhile to be able to improve better care for pets.

Investing in leadership development

Leadership and continuous development and specialization is critical for AniCura's ability to attract, retain and further develop the people needed for the transformation of the veterinary industry that AniCura started. As a result, AniCura launched a Leadership & Business development programme for all leaders.  Also offered is the AniCura Graduate programme, an immersive two-year development programme for new veterinarians.

The full report can be found on our website www.anicuragroup.com

CONTACT:

Linda Nyberg
AniCura Group Communications Director
+46 760061915
[email protected]

AniCura

Vendevägen 89 
182 32 Danderyd 
Sweden
www.anicuragroup.com

AniCura® Shaping the future of veterinary care

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/anicura/r/anicura-presents-the-quality-and-sustainability-report-for-2020,c3317978

The following files are available for download:

https://mb.cision.com/Main/1058/3317978/1395802.pdf

AniCura Quality & Sustainability Report 2020


These press releases may also interest you

11 mai 2024
eBlu Solutions, a leading provider of innovative technology solutions for the specialty healthcare industry, is pleased to announce the addition of Doug Lawrence to the Executive Leadership team in the role of Chief Revenue Officer. "We're not just...

11 mai 2024
NUVISTA Mental Health proudly announces its participation as a Gold Sponsor for the 2024 Ontario First...

11 mai 2024
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL?HF,...

11 mai 2024
Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at...

11 mai 2024
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology,...

11 mai 2024
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...



News published on and distributed by: